Revolax Deep side effects are a key consideration for any aesthetic medicine professional using this hyaluronic acid-based dermal filler. Understanding these effects, how to minimize risks, and implementing safe protocols is essential for clinical success.
In the field of aesthetic medicine, Revolax™ DEEP with Lidocaine (24 mg/ml HA + 3 mg/ml lidocaine, 1.1 ml prefilled syringe) has gained significant clinical traction for its performance in mid-to-deep dermal and supraperiosteal indications. As with all hyaluronic acid-based dermal fillers, understanding the potential side effects and safety measures is critical for ensuring optimal outcomes and maintaining patient trust.
This clinical guide is designed for trained aesthetic professionals seeking evidence-based insight into the side effect profile of REVOLAX™ DEEP, how to prevent complications, and best practices for safe injection protocols. In particular, this article focuses on Revolax Deep side effects and how to minimize clinical risk.
What is REVOLAX™ DEEP with Lidocaine?
REVOLAX™ DEEP is a monophasic, highly cross-linked dermal filler designed for deeper injections. It contains:
- 24 mg/ml non-animal hyaluronic acid
- 3 mg/ml lidocaine hydrochloride
- 1.1 ml prefilled syringe
Manufactured by Across Co. Ltd. in South Korea, REVOLAX is CE Class III certified and widely used in European, Asian, and UK markets.
Primary Indications:
- Nasolabial folds
- Marionette lines
- Chin augmentation
- Cheek and jawline contouring
More info: https://revolax.com
Common and Rare Side Effects of Hyaluronic Acid Fillers
All dermal fillers carry the possibility of side effects, most of which are mild and transient. However, understanding the clinical spectrum is vital.
Table 1: Common and rare reactions
| Side Effect | Frequency | Notes |
|---|---|---|
| Swelling / redness | Common | Resolves in 2–5 days |
| Bruising | Common | Use cold compress, avoid anticoagulants |
| Nodules | Uncommon | May require massage or hyaluronidase |
| Inflammatory reaction | Rare | Monitor, may need corticosteroids |
| Vascular occlusion | Very rare | Emergency; treat with hyaluronidase |
| Allergic reaction | Rare | Screen for lidocaine sensitivity |
Why REVOLAX™ DEEP Is Safe When Applied Correctly
REVOLAX™ DEEP is manufactured under strict quality protocols and does not contain residual BDDE. Its monophasic structure offers high cohesion, stability, and uniform integration.
- Biocompatible, non-animal HA
- Minimal product migration
- Highly purified gel
While no filler is without risk, published data and clinical use across thousands of cases have demonstrated a low incidence of adverse events when administered by qualified professionals.
Preventing Complications: Clinical Best Practices
Table 2: Key preventive strategies
| Risk Factor | Prevention Tip |
| Overfilling | Follow recommended volume per zone |
| Poor injection technique | Train in facial anatomy and filler rheology |
| Vessel injury | Use cannula when indicated; aspirate if needed |
| Unsanitary conditions | Maintain sterile field and glove protocol |
| Incomplete history | Screen for allergies and prior filler issues |
Additional tips:
- Inject slowly and with minimal pressure
- Avoid high-risk areas without advanced training
- Provide patients with written aftercare instructions
Managing Adverse Events in Practice
Prompt recognition and action can mitigate most complications:
- Nodules: Massage, hyaluronidase, topical corticosteroids
- Prolonged edema: Evaluate for hypersensitivity; anti-inflammatory measures
- Vascular compromise: Immediate use of hyaluronidase; refer if needed
- Infection: Consider antibiotic if signs persist
Reference: https://doi.org/10.2147/CCID.S80446
Interaction with Other Aesthetic Treatments
REVOLAX™ DEEP can be used alongside many other aesthetic modalities, provided proper scheduling and clinical assessment are followed.
Table 3: Combination treatment guidelines
| Treatment Type | Recommended Interval Before/After REVOLAX |
| Botulinum toxin (e.g., Botox) | 1–2 weeks before or after filler |
| Laser resurfacing | 2–4 weeks after filler |
| Microneedling | 1 week before or 2 weeks after |
| Chemical peels | 1 week before; avoid deep peels post-injection |
| Radiofrequency | At least 2 weeks before or after |
Combining procedures requires an understanding of tissue behavior and recovery phases. Practitioners should develop patient-specific treatment plans.
Post-Treatment Care and Patient Instructions
Post-care is essential to reduce side effects and optimize results. Recommended guidelines include:
- Avoid strenuous activity, alcohol, and heat exposure for 24–48 hours
- Apply cold compress if needed
- Sleep with head elevated first night
- Avoid touching or massaging treated areas unless instructed
- Follow-up consultation within 1–2 weeks
Providing printed aftercare sheets reinforces professionalism and minimizes patient anxiety.
Case Scenario: Chin Augmentation with REVOLAX™ DEEP
A 38-year-old female presents for chin enhancement. The clinician selects REVOLAX™ DEEP due to its high viscosity and lifting capacity. A blunt-tip 25G cannula is used in the supraperiosteal plane, injecting 0.6 ml bilaterally. No complications occur. Follow-up at 2 weeks shows well-integrated volume and high patient satisfaction.
This illustrates REVOLAX™ DEEP’s stability and precision in structural applications.
Talking to Patients: Educating Without Creating Fear
- Emphasize that minor swelling or bruising is expected and temporary
- Reinforce that complications are rare and manageable
- Communicate your training and safety protocols
- Highlight that REVOLAX is CE certified and clinically tested
Summary Table: REVOLAX™ DEEP Safety Profile
| Attribute | Specification |
| HA concentration | 24 mg/ml |
| Lidocaine | 3 mg/ml |
| Syringe volume | 1.1 ml |
| Technology | Monophasic, highly cross-linked |
| CE marked | Yes (Class III device) |
| FDA approved | No (sold in EU, UK, Asia) |
| Common effects | Mild bruising, swelling |
| Risk of serious events | Very low under professional use |
Final Considerations for Medical Professionals
REVOLAX™ DEEP offers a favorable safety profile, predictable results, and high patient satisfaction when used by trained clinicians. The key to safe and effective outcomes lies in:
- Patient selection
- Injection technique
- Post-treatment care
- Transparent patient communication
- Understanding treatment sequencing with other modalities
This guide is intended to support informed, professional practice and does not replace hands-on training or product certification.
References and Sources
- REVOLAX official: https://revolax.com
- Across Co. Ltd. technical data
- Sundaram H, et al. Dermatol Surg. 2015. https://pubmed.ncbi.nlm.nih.gov/25919247
- De Boulle K, Heydenrych I. CCID. 2015. https://doi.org/10.2147/CCID.S80446
- AMWC Aesthetic Complication Guidelines (2023)
- ISAPS Scientific Recommendations (2022)